A Phase 4 interventional study of Polihexanide-based bundle and Standard bundle in Surgical Site Infection and Surgical Procedures, Operative, sponsored by Marco Catarci. Not yet recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by Marco Catarci · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Surgical Wound Infection with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Surgical Wound Infection · Italy.
Among the 20 studies in Surgical Wound Infection with a site in Italy, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 4, and was the 18th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →3 of the 20 studies in Surgical Wound Infection with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Aesculap AG · Sites in Italy, Malaysia, Korea, Republic of and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 2,000 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 196 across the 13 interventional studies, 2,998 across the 7 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Marco Catarci as lead sponsor.
Marco Catarci has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
1 of the studies in Surgical Wound Infection with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07275307IRCCS Policlinico S. DonatoImpact of Prontosan Wound Gel X on Surgical Site Infections in Cardiac Surgery | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Surgical Wound Infection with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized controlled, prospective, multicenter superiority trial with two parallel treatment groups and single blinding (local investigators performing postoperative follow up will be blinded for group allocation), with prospective enrollment planned from July 2024 to June 2025 in 20 Italian surgical centers. All patients undergoing elective major gastro-intestinal (GI) tract surgery (upper GI, HPB, \& lower GI) will be included in a prospective database after written informed consent. A total of 2,000 patients is expected based on a mean of 100 cases per center.
Just after signing a written informed consent to participate, patients will randomly be assigned either to the experimental group (Polihexanide bundle) or to the control group. Block randomization (blocks of 10 patients per single participating center) will be performed using an unstratified computer generated randomization list. All operations will be performed according to local criteria of the participating center. Hair removal will be accomplished on the day of surgery with electronic clippers. Alcohol-based solutions of chlorhexidine for surgical site skin preparation will be used. A first dose of perioperative i.v. antibiotics will be administered 30 minutes before skin incision (choice of the antibiotic according to local criteria) in all patients. Additional intraoperative doses will be administered for procedures exceeding two half-lives of the antibiotic. At the end of the operation, the peritoneal cavity will be rinsed routinely with 0.9% sodium chloride solution (normal saline, NS) at body temperature. Before closure of fascia, instruments and gloves will be changed. The eventual placement of drain(s) in the peritoneal cavity and/or creation of an intestinal stoma will be recorded. No subcutaneous suture or drainage will be done. Skin will be closed with either staples, intracutaneous running suture or interrupted sutures.
Potential patient-specific and intraoperative risk factors will be recorded: sex, age, body mass index, nutritional status, frailty, indication to surgery (benign vs. malignant disease), perioperative administration of steroids, renal failure and dialysis, cardiovascular or respiratory disease, American Society of Anesthesiologist class, bowel preparation, type of approach, operative time, presence of peritoneal cavity drainage. During the postoperative period, patients will be examined by the attending surgeon daily. Fever (central temperature > 38 °C), pulse, abdominal signs, bowel movements, volume and aspect of drainage (if present) will be recorded daily. The local attending surgeon will make any decision for complementary exams and imaging according to his own criteria. The rate of any adverse event will be calculated and graded according to the Clavien-Dindo criteria [19] and to Japan Clinical Oncology Group Postoperative Complications (JCOG-PC) extended criteria [20], including all anastomotic leaks, wound infection (according to the definitions of the Centers for Disease Control and Prevention and wound culture), pneumonia (clinical symptoms, and physical and radiological examinations), central venous line infection (positive blood culture), urinary tract infection (positive urine culture with bacterial count). ERAS pathway items will be defined according to national [27] guidelines, measuring adherence upon explicit criteria. All data will be recorded for a minimum of 8 weeks (60 days) after surgery. PROM questionnaires will be administered to all enrolled patients four to one week before the planned operation, at discharge, and 6 to 8 weeks after the operation.
After anonymization, all data of each single case will be prospectively uploaded by local investigator(s) on a web-based database, protected by individual access credentials, and incorporated into a spreadsheet for data analysis. Any eventual discrepancy and/or mismatch will be checked, addressed and solved through strict cooperation between coordinating and local investigators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once a day starting 5 days before the operation: Total body washing with usual soap/shampoo and single-use washcloths impregnated with a mix of Polihexanide, surfactants, and excipients. Nasal cleaning 3 times a day with a Polihexanide Nasal Gel Oral gargles 3 times a day using 10 mL of a Polihexanide oral solution. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) of antiseptic solution will be performed using a 0.04% sterile Polihexanide solution. After the end of the application time, a subcutaneous swab for culture will be taken. Before standard (according to local center clinical practice) wound(s) dressing(s), a 3 mm-thick antiseptic gel (a combination comprised of 0.1 % Polihexanide and 0.1 % propyl betaine (surfactant) that is used for cleansing, moistening and decontamination of post-operative wounds) will be applied on any wound(s).
Combination Product: Polihexanide-based bundle
Once a day starting 5 days before the operation: Total body washing with usual soap/shampoo. No oral and nasal MDRO-decolonization will be performed. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) NS will be performed. After the end of the application time, a subcutaneous swab for culture will be taken. Finally, standard wound(s) dressing(s) (according to local center clinical practice) will be applied.
Combination Product: Standard bundle
Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
Also known as: Prontoderm® Wipes (B. Braun Medical AG, Sempach, Switzerland), Prontoderm® Nasal Gel (B. Braun Medical AG, Sempach, Switzerland), ProntOral® (B. Braun Medical AG, Sempach, Switzerland), LavaSurge® (B. Braun Medical AG, Sempach, Switzerland)
Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
Surgical Site Infections rate
CDC definition
Time frame: 60 days after surgery
Incisional (superficial and deep) Surgical Site Infections rate
CDC definition
Time frame: 60 days after surgery
Infectious morbidity rates
SSI + urinary tract infection + pulmonary infection
Time frame: 60 days after surgery
Anastomotic leakage rates
According to international consensus
Time frame: 60 days after surgery
Overall morbidity rates
Any adverse event
Time frame: 60 days after surgery
Major morbidity rates
Any adverse event grade \> II according to Clavien-Dindo
Time frame: 60 days after surgery
Comprehensive complication index
According to Slankamenac et al 2013
Time frame: 60 days after surgery
Overall length of postoperative hospital stay
inclusive of any unplanned readmission
Time frame: 60 days after surgery
Readmission rates
any unplanned readmission after primary discharge
Time frame: 60 days after surgery
Patient-reported outcome measures
MD Anderson Symptom Inventory for Gastrointestinal Surgery
Time frame: preoperative, at discharge, 60 days after surgery
Plan to share: Undecided — complete dataset after study completion will be availble upon request
Start is estimated for Jul 2024; primary completion for Jun 2025, 11 months later.
Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 11 months is below that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.